DNA Q4 2024 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M+26.2% YoY

Gross Profit

$34M78.1% margin

Operating Income

-$104M-236.3% margin

Net Income

-$108M-245.2% margin

EPS (Diluted)

$-2.07

QoQ Revenue Growth

-50.8%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$56M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$661M

Stockholders' Equity

$716M

Cash & Equivalents

$562M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$35M	+26.2%
Gross Profit	$34M	$28M	+21.6%
Operating Income	-$104M	-$178M	+41.8%
Net Income	-$108M	-$212M	+49.2%

Revenue Segments

Service

$39M100%